RxDoctor Payments Data

Elysa Marco

Neurodevelopmental Disabilities · San Francisco, CANPI 1518032713

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $10,000 of the $10,037 with a category attached, or 99.6%. Sage Therapeutics, LLC accounts for 99.6% of it on its own, with 1 other manufacturer making up the rest.

$10,037in general payments, 2019–2025

Across 7 payments — averaging $1433.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sage Therapeutics, LLC$10K
  • Astellas Pharma US Inc$37
$651,250in research payments, 2019–2025

Across 47 payments — averaging $13,856 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Acadia Pharmaceuticals Inc$651K

What the payments were for

  • Consulting fees$10,000100%
  • Food & beverage$370%

General payments by program year

22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sage Therapeutics, LLC6$10,000
Astellas Pharma US Inc1$37

How this compares

$10,037 in reported general payments places this provider in the 75th percentile of 21 neurodevelopmental disabilities providers in California.

See all neurodevelopmental disabilities providers in California →

Most prescribed under Part D

DrugClaimsCost to plans & patients
ValtocoDiazepam12$9,939
Lamotrigine ErLamotrigine17$6,781
Propranolol Hcl14$811
Olanzapine16$741
Trazodone Hcl24$601
Buspirone Hcl18$430
Clonazepam13$6

Paid to pharmacies, not to this prescriber.

Other neurodevelopmental disabilities in San Francisco

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →